Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
作者： C Pepper , A G S Buggins , C H Jones , E J Walsby , F Forconi
DOI: 10.1038/LEU.2014.308
关键词:
摘要: The majority of chronic lymphocytic leukemia (CLL) patients are diagnosed with early-stage disease but the currently used prognostic tools appear to be less informative in this group patients.1 This is especially problematic for mutated immunoglobulin genes (M-CLL) as they have a more diverse clinical course when compared unmutated (U-CLL).1, 2, 3, 4 Given emergence promising targeted, toxic, therapeutics CLL,5, 6 there an increased need identify who might benefit from early treatment these new agents.
sussex.ac.uk
core.ac.uk
nature.com
sci-hub.se 参考文章(15)
Stuart M. Lichtman, Philip Schulman, Vincent P. Vinciguerra, Kanti R. Rai, Manlio Ferrarini, Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil, Franco Fais, Fabio Ghiotto, Angelo Valetto, Steven L. Allen, Aby Buchbinder, Daniel Budman, Klaus Dittmar, Jonathan Kolitz, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. ,vol. 94, pp. 1840- 1847 ,(1999) , 10.1182/BLOOD.V94.6.1840
Terry J. Hamblin, Zadie Davis, Anne Gardiner, David G. Oscier, Freda K. Stevenson, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. ,vol. 94, pp. 1848- 1854 ,(1999) , 10.1182/BLOOD.V94.6.1848
Chris Pepper, Aneela Majid, Thet Thet Lin, Saman Hewamana, Guy Pratt, Renata Walewska, Stefan Gesk, Reiner Siebert, Simon Wagner, Ben Kennedy, Fiona Miall, Zadie A Davis, Ian Tracy, Anne C Gardiner, Paul Brennan, Robert K Hills, Martin JS Dyer, David Oscier, Chris Fegan, None, Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology. ,vol. 156, pp. 499- 507 ,(2012) , 10.1111/J.1365-2141.2011.08974.X
GERARD TOBIN, OLA SÖDERBERG, ULF THUNBERG, RICHARD ROSENQUIST, VH3-21 Gene Usage in Chronic Lymphocytic Leukemia – Characterization of a New Subgroup with Distinct Molecular Features and Poor Survival Leukemia & Lymphoma. ,vol. 45, pp. 221- 228 ,(2004) , 10.1080/1042819031000147018
Elisabeth Walsby, Andrea Buggins, Stephen Devereux, Ceri Jones, Guy Pratt, Paul Brennan, Chris Fegan, Chris Pepper, Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood. ,vol. 123, pp. 3607- 3617 ,(2014) , 10.1182/BLOOD-2013-12-544569
Aneela Majid, Thet Thet Lin, Giles Best, Keith Fishlock, Saman Hewamana, Guy Pratt, Deborah Yallop, Andrea GS Buggins, Simon Wagner, Ben J Kennedy, Fiona Miall, Robert Hills, Stephen Devereux, David G Oscier, Martin JS Dyer, Chris Fegan, Chris Pepper, None, CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL Leukemia Research. ,vol. 35, pp. 750- 756 ,(2011) , 10.1016/J.LEUKRES.2010.10.022
Douglas E. Gladstone, Amanda Blackford, Eunpi Cho, Lode Swinnen, Yvette Kasamon, Christopher D. Gocke, Constance A. Griffin, Javier Bolaños-Meade, Richard J. Jones, The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia Clinical Lymphoma, Myeloma & Leukemia. ,vol. 12, pp. 132- 137 ,(2012) , 10.1016/J.CLML.2011.12.005
Sabine Ponader, Shih-Shih Chen, Joseph J. Buggy, Kumudha Balakrishnan, Varsha Gandhi, William G. Wierda, Michael J. Keating, Susan O'Brien, Nicholas Chiorazzi, Jan A. Burger, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. ,vol. 119, pp. 1182- 1189 ,(2012) , 10.1182/BLOOD-2011-10-386417
Jan A. Burger, Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Seminars in Cancer Biology. ,vol. 20, pp. 424- 430 ,(2010) , 10.1016/J.SEMCANCER.2010.09.005
John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Y. Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O'Brien, Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia The New England Journal of Medicine. ,vol. 369, pp. 32- 42 ,(2013) , 10.1056/NEJMOA1215637